Association between levels of MPA and complications in SLE
发布日期:
2024-07-23
浏览次数:
0

PREAMBLE

Systemic lupus erythematosus (SLE) is a common chronic autoimmune disease, also more common in children, called cSLE, with an incidence of 0.3-0.9 cases per 100,000 people. Mycophenolate mofetil (MMF), a commonly used drug for the treatment of cSLE, is converted in vivo to mycophenolic acid (MPA) in the active state, which inhibits the rate-limiting enzyme, inosine monophosphate dehydrogenase, and thus inhibits the pathway for the de novo synthesis of purines in T- and B-lymphocytes.

In order to obtain better clinical outcomes, clinical trials have been conducted to explore MPA concentration targets using therapeutic drug monitoring (TDM). However, the occurrence of complications during the treatment of cSLE has been a major clinical concern, especially the morbidity and mortality associated with renal injury, which is more common in children than in adults. Therefore, there is a need to investigate the relationship between MPA exposure levels and comorbidities.





Results



The researchers enrolled 107 children with SLE from Children's Hospital of Fudan University between 2015 and 2021, and recorded their medication intake, complication status, and MPA drug concentration (four time points: 0 min (C0), 20 min (C20), 60 min (C60), and 180 min (C180)).

By analyzing the relationship between complications and AUC0-24h, and each blood collection time point, it was seen that diabetes mellitus, acute kidney injury, and pneumonia had a significant negative correlation with AUC0-24h (P values of 0.022, 0.021, and<0.001, respectively). Chronic kidney disease had a significant positive correlation with MPA trough concentration C0 (P<0.001). Nephritis was significantly positively correlated with C20, C60, and C180 (P=0.04). The results are shown in the figure below.


Association between levels of MPA and complications in SLE

在分析生化检测、血常规、SLE活动指数(SLEDAI)与MPA暴露水平的相关性分析中显示,ALB、TBIL、LYM%与AUC0-24h正相关,而ALT、WBC数、SLEDAI则与AUC0-24h负相关。但是这些相关性在用其他MPA暴露的评判指标进行衡量时则并不显示有明显的相关趋势。



Conclusion


During the treatment of cSLE, the incidence of complications in patients with can be predicted by the level of MPA exposure represented by AUC0-24h. Regression analyses showed that AUC0-24h was a significant predictor of the incidence of diabetes, AKI, and pneumonia, and that high exposure levels were associated with low incidence. An AUC0-24h of 100.39 mg·h/L or an AUC0-12h of 50.20 mg·h/L can be used as a target exposure level for the clinical treatment of children with SLE. These findings provide support for clinical practice in preventing comorbidities in children with SLE.



Diagreat



Therapeutic Drug Monitoring - Fully Automated Chemiluminescent Solution


Association between levels of MPA and complications in SLE

Association between levels of MPA and complications in SLE

Association between levels of MPA and complications in SLE





END



Related Recommendations